231 related articles for article (PubMed ID: 18250617)
1. Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome.
Fusco A; Bianchi A; Mancini A; Milardi D; Giampietro A; Cimino V; Porcelli T; Romualdi D; Guido M; Lanzone A; Pontecorvi A; De Marinis L
J Endocrinol Invest; 2007 Dec; 30(11):948-56. PubMed ID: 18250617
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
3. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
4. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin.
Guido M; Romualdi D; De Marinis L; Porcelli T; Giuliani M; Costantini B; Lanzone A
Fertil Steril; 2007 Jul; 88(1):125-30. PubMed ID: 17276431
[TBL] [Abstract][Full Text] [Related]
5. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
Orio F; Palomba S; Colao A; Russo T; Dentico C; Tauchmanovà L; Savastano S; Nappi C; Sultan C; Zullo F; Lombardi G
J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
[TBL] [Abstract][Full Text] [Related]
6. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
7. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.
Pagotto U; Gambineri A; Vicennati V; Heiman ML; Tschöp M; Pasquali R
J Clin Endocrinol Metab; 2002 Dec; 87(12):5625-9. PubMed ID: 12466363
[TBL] [Abstract][Full Text] [Related]
8. Alterations in nonesterified free fatty acid trafficking rather than hyperandrogenism contribute to metabolic health in obese women with polycystic ovary syndrome.
Ezeh U; Chen YI; Pall M; Buyalos RP; Chan JL; Pisarska MD; Azziz R
Fertil Steril; 2024 Jun; 121(6):1040-1052. PubMed ID: 38307453
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity.
Tassone F; Broglio F; Destefanis S; Rovere S; Benso A; Gottero C; Prodam F; Rossetto R; Gauna C; van der Lely AJ; Ghigo E; Maccario M
J Clin Endocrinol Metab; 2003 Nov; 88(11):5478-83. PubMed ID: 14602793
[TBL] [Abstract][Full Text] [Related]
10. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
Ciampelli M; Muzj G; Leoni F; Romualdi D; Belosi C; Cento RM; Lanzone A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5324-9. PubMed ID: 11701699
[TBL] [Abstract][Full Text] [Related]
12. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.
Lanzone A; Villa P; Fulghesu AM; Pavone V; Caruso A; Mancuso S
Hum Reprod; 1995 Jul; 10(7):1653-7. PubMed ID: 8582956
[TBL] [Abstract][Full Text] [Related]
13. A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS).
Daghestani MH; Daghestani M; Daghistani M; El-Mazny A; Bjørklund G; Chirumbolo S; Al Saggaf SH; Warsy A
Lipids Health Dis; 2018 Aug; 17(1):195. PubMed ID: 30131073
[TBL] [Abstract][Full Text] [Related]
14. Decreased soluble leptin receptor levels in women with polycystic ovary syndrome.
Hahn S; Haselhorst U; Quadbeck B; Tan S; Kimmig R; Mann K; Janssen OE
Eur J Endocrinol; 2006 Feb; 154(2):287-94. PubMed ID: 16452543
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
16. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
17. Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients.
Villa P; Fulghesu AM; De Marinis L; Valle D; Mancini A; Pavone V; Caruso A; Lanzone A
Metabolism; 1997 May; 46(5):538-43. PubMed ID: 9160821
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls.
Glintborg D; Andersen M; Hagen C; Frystyk J; Hulstrøm V; Flyvbjerg A; Hermann AP
Eur J Endocrinol; 2006 Aug; 155(2):337-45. PubMed ID: 16868149
[TBL] [Abstract][Full Text] [Related]
19. Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters.
Chapman IM; Wittert GA; Norman RJ
Clin Endocrinol (Oxf); 1997 Feb; 46(2):175-81. PubMed ID: 9135699
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
